{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:10:42Z","timestamp":1789679442162,"version":"4.0.1"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Sex (biological attributes associated with being male or female) and gender (sociocultural-driven traits and behaviors related to being a man or a woman) are emerging as important determinants of disease course and response to therapy in patients with psoriasis and psoriatic arthritis (PsA). Although psoriatic disease (PsD) is equally prevalent in men and women, the condition affects them in different and unique ways, giving rise to sex- and gender-related differences in clinical presentation, including baseline disease activity, disease course, and response to treatment. Better understanding of the roles sex and gender play in the development and evolution of PsD has the potential to improve patient care. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) continues its effort to highlight issues related to diversity, equity, and inclusion in people with PsD by dedicating a session during the annual meeting to sex and gender and their intersectionality with race and ethnicity in individuals with PsA.<\/jats:p>","DOI":"10.3899\/jrheum.2023-0525","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T12:20:24Z","timestamp":1690892424000},"page":"38-40","source":"Crossref","is-referenced-by-count":3,"title":["Diversity, Equity, and Inclusion: Sex and Gender and Intersectionality With Race and Ethnicity in Psoriatic Disease"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5002-2345","authenticated-orcid":false,"given":"Alaina J.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-9915","authenticated-orcid":false,"given":"Irene","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-5157","authenticated-orcid":false,"given":"Niti","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"2023110105251437000_50.Suppl_2.38.1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2023110105251437000_50.Suppl_2.38.2","doi-asserted-by":"crossref","first-page":"849560","DOI":"10.3389\/fimmu.2022.849560","article-title":"Sex-based medicine meets psoriatic arthritis: lessons learned and to learn","volume":"13","author":"Bragazzi","year":"2022","journal-title":"Front Immunol"},{"key":"2023110105251437000_50.Suppl_2.38.3","doi-asserted-by":"crossref","first-page":"e2029650","DOI":"10.1001\/jamanetworkopen.2020.29650","article-title":"Patient-reported experiences of discrimination in the US health care system","volume":"3","author":"Nong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2023110105251437000_50.Suppl_2.38.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16405"},{"key":"2023110105251437000_50.Suppl_2.38.5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jama.2021.13304","article-title":"Updated guidance on the reporting of race and ethnicity in medical and science journals","volume":"326","author":"Flanagin","year":"2021","journal-title":"JAMA"},{"key":"2023110105251437000_50.Suppl_2.38.6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","article-title":"Sex and gender equity in research: rationale for the SAGER guidelines and recommended use","volume":"1","author":"Heidari","year":"2016","journal-title":"Res Integr Peer Rev"},{"key":"2023110105251437000_50.Suppl_2.38.7","doi-asserted-by":"crossref","first-page":"iv38","DOI":"10.1093\/rheumatology\/keaa543","article-title":"Sex and gender differences in axial spondyloarthritis: myths and truths","volume":"59","author":"Rusman","year":"2020","journal-title":"Rheumatology"},{"key":"2023110105251437000_50.Suppl_2.38.8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-022-00833-0","article-title":"Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis","volume":"18","author":"Stovall","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2023110105251437000_50.Suppl_2.38.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.04.027"},{"key":"2023110105251437000_50.Suppl_2.38.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202431"},{"key":"2023110105251437000_50.Suppl_2.38.11","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s40744-021-00380-2","article-title":"A pooled analysis reporting the efficacy and safety of secukinumab in male and female patients with ankylosing spondylitis","volume":"8","author":"van der Horst-Bruinsma","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2023110105251437000_50.Suppl_2.38.12","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1007\/s12325-022-02132-2","article-title":"Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis through 52 weeks: data from three Phase III randomised controlled trials","volume":"39","author":"van der Horst-Bruinsma","year":"2022","journal-title":"Adv Ther"},{"key":"2023110105251437000_50.Suppl_2.38.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211037"},{"key":"2023110105251437000_50.Suppl_2.38.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key140"},{"key":"2023110105251437000_50.Suppl_2.38.15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","article-title":"Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials","volume":"9","author":"Eder","year":"2022","journal-title":"Rheumatol Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-0525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:31:52Z","timestamp":1698841912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-0525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":15,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.3899\/jrheum.2023-0525"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-0525","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}